Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | CA7 | P43166 | 4/20 | 0.60 |
| ▸ | XDH | P47989 | 4/20 | 0.60 |
| ▸ | BCHE | P06276 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | ACHE | P22303 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | TRPC5 | Q9UL62 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056298 | 0.86 | ABCB1 (0.55) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL119434 | 0.84 | MEN1 (0.64) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL5133662 | 0.81 | NOX4 (0.73) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL118852 | 0.81 | ABCB1 (0.56) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL3755551 | 0.80 | MEN1 (0.69) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL13056264 | 0.80 | CYP1A2 (0.69) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL120585 | 0.80 | CYP1A2 (0.67) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| Galangin SCHEMBL117225 | 0.76 | MEN1 (1.00) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| Galangin SCHEMBL29393121 | 0.76 | MEN1 (1.00) | MEN1KMT2AABCB1CYP3A4CYP1A1 | |
| SCHEMBL13056280 | 0.76 | MEN1 (0.52) | MEN1KMT2AABCB1CYP3A4CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424541-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | Limerick BioPharma, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010129138-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129138-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | MEN1 2302/4885KMT2A 4512/4885ABCB1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.